Topics

FDA approves Grifols’ Xembify to treat primary immunodeficiencies

03:15 EDT 5 Jul 2019 | Pharmaceutical Business Review

According to the company, Xembify (immune globulin subcutaneous, human- klhw) is a 20% immune globulin solution for subcutaneous injection indicated to treat primary humoral immunodeficiency (PI) in patients

The post FDA approves Grifols’ Xembify to treat primary immunodeficiencies appeared first on Pharmaceutical Business review.

Original Article: FDA approves Grifols’ Xembify to treat primary immunodeficiencies

NEXT ARTICLE

More From BioPortfolio on "FDA approves Grifols’ Xembify to treat primary immunodeficiencies"

Quick Search